+++ Thermosome Initiates Final Dose Level in Phase I Trial of Lead compound THE001 +++
+++ SciRhom announces first dosing in First-in-Man trial for lead program SR-878 +++
+++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA +++
+++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. +++
+++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 +++
+++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 +++
+++ Tubulis secures significant EUR 128 million Series B2 financing +++
+++ Novel small molecule drugs of the future targeting the CNS +++
+++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) +++
+++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level +++
+++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis +++
+++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments +++
+++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq +++
+++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million +++
+++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 +++
+++ Renowned Peutinger-Collegium visits the IZB +++
+++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 +++
+++ GoingPublic celebrates a quarter century of biotech +++
+++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency +++
+++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell +++
+++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology +++
+++ High-Profile Clinical Advisory Board for Thermosome +++
+++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker +++
+++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation +++
+++ adivo becomes part of the world’s leading animal health company Zoetis +++
+++ The Munich Bavaria Student Union visits the IZB +++
+++ Bind-X secures €10 million in financing as part of its Series B financing round +++
+++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research +++
+++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program +++
+++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub +++
+++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy +++
+++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease +++
+++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO +++
+++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB +++
+++ Japanese delegation visits the IZB +++
+++ Bavarian biotechnology maintains its position in the crisis and continues to grow +++
+++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board +++
+++ Official handover ceremony at the Annual Meeting of the Max Planck Society +++
+++ Secarna appoints new Chief Business Officer +++
+++ Bicoll showcases at BIO International Convention +++
+++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma +++
+++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry +++
+++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies +++
+++ Biotech report by vfa: Biopharmaceuticals successfully gain market share +++
+++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa +++
+++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics +++
+++ Non-nutritive sweeteners may affect the human immune system +++
+++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” +++
+++ Invitris receives 250,000 EUR to complete spin-out from TUM +++
+++ Eisbach starts phase I clinical trial with COVID-19 antiviral +++
+++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park +++
+++ Specific packaging of DNA affects cell division +++
+++ Tubulis Enters Strategic Partnership with BMS +++
+++ Insempra launches its first functional component for consumer goods +++
+++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman +++
+++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease +++
+++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership +++
+++ adivo expands into new headquarters as first clinical study begins +++
+++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial +++
+++ Construction of the “New Hauner” at the Grosshadern Campus has started +++
+++ Insempra names new Chief Operating Officer +++
+++ Training events for project managers and biological safety officers +++
+++ The zebrafish brain as a map +++
+++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure +++
+++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris +++
+++ When life begins too early +++
+++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease +++
+++ Expansion of the Munich “science line” has started +++
+++ Enno Spillner to join Formycon as CFO +++